Radar Open Radar

Moderna shares crashed 17.5% after it shared on social media details from a conserved mRNA-based cancer vaccine study, raising concerns that the treatment may not be as effective as initially expected.

Insider Paper · Source

Moderna shares crashed 17.5% after it shared on social media details from a conserved mRNA-based cancer vaccine study, raising concerns that the treatment may not be as effective as initially expected.

Moderna shares crashed 17.5% after it shared on social media details from a conserved mRNA-based cancer vaccine study, raising concerns that the treatment may not be as effective as initially expected.